Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center (C-PROBE)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by University of Michigan.
Recruitment status was  Recruiting
St. John Health System, Michigan
University of Illinois at Chicago
Wayne State University
Information provided by:
University of Michigan Identifier:
First received: November 18, 2009
Last updated: April 7, 2011
Last verified: April 2011
More than 10 million Americans have chronic kidney disease and every year, approximately 100,000 new patients develop end stage renal disease (ESRD) resulting in incalculable human suffering, a high rate of premature mortality, catastrophic physical and emotional disability and prohibitive costs to the U.S. health care system. The current medical therapies for chronic kidney disease, which disproportionately affect African Americans and other minority groups and account for 70% of ESRD, cases are woefully inadequate. This O'Brien Kidney Research Core will create opportunities for novel insights through characterization of tissue profiles that will define new disease markers and molecular pathways and will be available to all kidney investigators on the www. It will thereby fundamentally alter the starting point for research into prevention of progression of these kidney diseases. C-PROBE is an essential element of the center grant and presents a biomedical resource core consisting of: (1) clinical phenotyping (that is, systematic identification of observable physical and biomedical characteristics) of kidney disease patients including the accurate measurement of kidney function; and (2) a specimen BioBank which will store blood, urine and kidney tissue samples . A key component of C-PROBE is therefore that it contains a proven mechanism to collect samples from high risk groups including minorities, that will feed the other Cores and provide biomedical investigators at the institutions of University of Michigan Health System, St. John Hospital, Wayne State University in Michigan and University of Illinois in Chicago access to a dynamic pool of well characterized high risk kidney disease patients and their biological specimens to conduct high caliber translational research.

Chronic Kidney Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center

Resource links provided by NLM:

Further study details as provided by University of Michigan:

Biospecimen Retention:   Samples With DNA
Urine, blood and renal tissue, if available

Estimated Enrollment: 1500
Study Start Date: January 2009
Chronic Kidney Disease Cohort
Matched Control Group


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Nephrology clinic patients and community members

Inclusion Criteria:

  • persons of any age who have chronic kidney disease (abnormally high protein in urine or reduced kidney function determined by blood tests)
  • a small number of people without chronic kidney disease

Exclusion Criteria:

  • people on hemodialysis or peritoneal dialysis
  • people who have had a kidney transplant
  • people unable or unwilling to provide consent
  • women who are pregnant or nursing
  • people who have polycystic kidney disease
  • people with a hemoglobin of <9 at the time of enrollment
  • institutionalized persons
  • people currently participating in a blinded interventional clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01016613

United States, Illinois
University of Illinois at Chicago Recruiting
Chicago, Illinois, United States, 60612
Contact: Alberto Cabrales    312-996-2937   
Principal Investigator: Kalyani Perumal, MD         
United States, Michigan
University of Michigan Health System Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Jennifer J Hawkins, MPH    734-615-8304   
Contact: Chrysta Lienczewski, BS    734-615-5021   
Principal Investigator: Crystal A Gadegbeku, MD         
Wayne State University Recruiting
Detroit, Michigan, United States, 48201
Contact: Carol Muzyk, CCRP    313-745-2378   
Principal Investigator: Kalyani Mehta, MD         
St. John's Health System Recruiting
Detroit, Michigan, United States, 48236
Contact: Sherry Gasko, RN, BSN    313-886-8787 ext 1264   
Contact: Tina Cavendish    313-886-8787 ext 1266   
Principal Investigator: Susan Steigerwalt, MD         
Sponsors and Collaborators
University of Michigan
St. John Health System, Michigan
University of Illinois at Chicago
Wayne State University
Principal Investigator: Frank C Brosius, MD University of Michigan
Study Director: Crystal A Gadegbeku, MD University of Michigan
Study Director: Matthias Kretzler, MD University of Michigan
  More Information

Responsible Party: Frank Brosius, MD, University of Michigan Health Systems Identifier: NCT01016613     History of Changes
Other Study ID Numbers: P30DK081943 
Study First Received: November 18, 2009
Last Updated: April 7, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by University of Michigan:
chronic kidney disease
nephrotic syndrome

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency processed this record on September 23, 2016